Dexmedetomidine (Dexdor®) is recommended as an option for use within NHS Wales for the sedation of adult intensive care unit (ICU) patients requiring a sedation level not deeper than arousal in response to verbal stimulation (corresponding to Richmond Agitation-Sedation Scale [RASS] 0 to -3).

In June 2022 the marketing authorisation holder issued a direct healthcare professional communication (DHPC) to share important information regarding an increased risk of mortality in intensive care unit (ICU) patients ≤ 65 years. The SmPC has been updated with a warning statement. The full DHCP can be accessed here.